{"success":true,"data":{"pressRelease":{"id":"131486","rtpr_id":"nPre3zKVLa","ticker":"IP40","exchange":"","all_tickers":["IP40"],"title":"Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)","author":"PR Newswire","published_at":"2026-08-31T20:01:00.515Z","article_body":"Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue\nof US$5.25M (CAD 7.3M)\nPR Newswire\n\nHERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026\n\nSecond Quarter 2026 Results: Gross Margin of 90.9% and Category Leadership\n\nHERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026 /PRNewswire/ -- Innocan\nPharma Corporation (CSE: INNO) (OTCQB: INNPF) (\"Innocan\" or the \"Company\"),\ntoday reported today 2026 financial consolidated results for the six and\nthree months ended June 30, 2026.\n\nInnocan's consumer wellness subsidiary. B.I. Sky Global Ltd. (\"BI Sky\"),\nsuccessfully maintained a gross margin of 90.9% during the period, reflecting\nthe strength of its product portfolio, direct-to-consumer business model and\ndisciplined approach to operations.\n\nVALITIC™ Maintains Leading Amazon Best Seller Position\n\nVALITIC™, the flagship skincare brand of B.I. Sky, continues to maintain a\nleading positions across key product categories on Amazon, including achieving\nthe leading ranking in its category. This performance reflects continued\nconsumer demand and the growing strength of the VALITIC™ brand.\n\nVALITIC™ continues to hold Amazon's \"Best Seller\" badge, recognizing its\nposition as the Top best-selling product in its specific category. The badge\nis based on actual sales performance rather than customer ratings and is\nupdated hourly according to sales volume, highlighting the brand's strong and\nsustained consumer demand.\n\nVALITIC™ also holds Amazon's Choice recognition, reflecting Amazon's\nalgorithmic recommendation based on factors including customer ratings, price\ncompetitiveness, availability, delivery performance and return rates.\n\n\"We are proud of the strength of BI Sky's business and the consumer trust\nbuilt around our products,\" said Iris Bincovich, CEO of Innocan Pharma\nCorporation. The Company's results were also impacted by the Trump\nadministration's frequently changing policies regarding customs duties and\ntariffs, which created significant uncertainty that led to a decline in sales\nin the period. However, the Company continues to maintain a strong balance\nsheet and solid liquidity position, with approximately $ US 6.4 million in\ncash and cash equivalents and $US10.37 million in total assets as of June 30,\n2026, providing a solid consolidated financial foundation to support its\nongoing operations and growth initiatives.\n\nRoni Kamhi, CEO of B.I. Sky  and COO of Innocan Pharma said \"Building on Our\nTop Amazon Ranking to Expand Sales Across Multiple Channels B.I. Sky is\nadvancing initiatives to diversify and expand its sales channels, building on\nits leading position on Amazon while broadening its market reach across\nmultiple platforms.\n\nAmazon will continue to represent an important sales channel. At the same\ntime, the Company is pursuing additional growth opportunities, including\nexpanding its relationships with major U.S. retail and distribution networks\nand increasing its presence across major online retail platforms. In parallel,\nB.I. Sky has begun selling through its own direct-to-consumer (DTC) website,\nwhich is already operational and provides an additional platform to build\ndirect relationships with consumers, strengthen brand engagement, and expand\nthe reach of the Valitic® brand.\nI believe that its established brands, product portfolio and existing customer\nbase provide a strong foundation for further growth. By leveraging these\nstrengths across a broader range of sales channels, the Company aims to\nincrease market reach, create additional revenue opportunities and strengthen\nits commercial performance. I expect these initiatives to support revenue\ngrowth and expand the reach and visibility of its brands over the coming year.\n\n\"With a greater focus on sales execution, broader distribution and continued\ninvestment in our core strengths, we believe B.I. Sky is well positioned to\nstrengthen its commercial performance and create long-term value for our\nshareholders,\" concluded Mr. Kamhi.\n\nFISCAL 2026 THREE MONTHS SELECT FINANCIAL RESULTS (unaudited) Consolidated\n\n (US$ in millions)        Three Months Ended      Percentage   \n                          June 30,                Change       \n                          2026        2025        \n Revenues                 5.25        7.01        (25.06 %)    \n Gross Profit             4.769       6.195       (23.0 %)     \n Gross Margin             90.8 %      88.4 %                   \n Operating Profit (Loss)  (0.508)     0.396       (228.3 %)    \n* Revenues totaled US$5.25 million for the three months ended June 30, 2026,\nOn a year-over-year basis, revenues decreased 25.06% compared to the same\nperiod in the prior year.\n* Gross Profit totaled US$4.769 million representing a decrease of 23.0% on a\nreported basis for the three months ended June 30, 2026.\n* Gross Margin remained high at 90.8% despite the decline in revenues in three\nmonths ended June 30, 2026.\n* Operating loss totaled US$0.508 million, representing an increase of 228.3%\non a reported basis for the three months ended June 30, 2026.\nThe Company's full set of unaudited condensed interim consolidated financial\nstatements for the three and six months ended June 30, 2026, and accompanying\nmanagement's discussion and analysis can be accessed by visiting the Company's\nwebsite at www.innocanpharma.com and its SEDAR+ profile\nat www.sedarplus.ca.\n\nAbout Innocan:\n\nInnocan is an innovator in the pharmaceuticals and wellness sectors. In the\nwellness sector, Innocan develops and markets a wide portfolio of\nhigh-performance self-care and beauty products to promote a healthier\nlifestyle. Under this segment Innocan carries on business through its 60%\nowned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted\nonline sales.\n\nwww.innocanpharma.com \n\nContact Information:\n\nFor Innocan Pharma Corporation:\nIris Bincovich, CEO\n+1 5162104025\n+972-54-3012842\n+442037699377\ninfo@innocanpharma.com\n\nNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER\nHAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS\nRELEASE.\n\nCaution Regarding Forward-Looking Information\n\nCertain information set forth in this news release, including, without\nlimitation,  consumer growth of the Valitic brand, is forward-looking\ninformation within the meaning of applicable securities laws. By its nature,\nforward-looking information is subject to numerous risks and uncertainties,\nsome of which are beyond Innocan's control. The forward-looking information\ncontained in this news release is based on certain key expectations and\nassumptions made by Innocan, including expectations and assumptions concerning\nthe anticipated benefits of the products, satisfaction of regulatory\nrequirements in various jurisdictions and satisfactory completion of\nproduction and distribution arrangements.\n\nForward-looking information is subject to various risks and uncertainties that\ncould cause actual results and experience to differ materially from the\nanticipated results or expectations expressed in this news release. The key\nrisks and uncertainties include but are not limited to: global and local\n(national) economic, political, market and business conditions; governmental\nand regulatory requirements and actions by governmental authorities; and\npotential disruption of relationships with suppliers, manufacturers,\ncustomers, business partners and competitors. There are also risks that are\ninherent in the nature of product distribution, including import/export\nmatters and the failure to obtain any required regulatory and other approvals\n(or to do so in a timely manner). The anticipated timeline for entry to\nmarkets may change for a number of reasons, including the inability to secure\nnecessary regulatory requirements, or the need for additional time to conclude\nand/or satisfy the manufacturing and distribution arrangements. As a result of\nthe foregoing, readers should not place undue reliance on the forward-looking\ninformation contained in this news release. A comprehensive discussion of\nother risks that impact Innocan can be found in Innocan's public reports and\nfilings which are available under Innocan's profile at www.sedarplus.ca.\n\nReaders are cautioned that undue reliance should not be placed on\nforward-looking information as actual results may vary materially from the\nforward-looking information. Innocan does not undertake to update, correct or\nrevise any forward-looking information as a result of any new information,\nfuture events or otherwise, except as may be required by applicable law.\n\nLogo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-second-quarter-fiscal-year-2026-results-with-revenue-of-us5-25m-cad-7-3m-302865166.html\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPre3zKVLa","title":"Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)","author":"PR Newswire","ticker":"IP40","created":"2026-08-31T20:01:00.515Z","tickers":["IP40"],"exchange":"","article_body":"Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue\nof US$5.25M (CAD 7.3M)\nPR Newswire\n\nHERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026\n\nSecond Quarter 2026 Results: Gross Margin of 90.9% and Category Leadership\n\nHERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026 /PRNewswire/ -- Innocan\nPharma Corporation (CSE: INNO) (OTCQB: INNPF) (\"Innocan\" or the \"Company\"),\ntoday reported today 2026 financial consolidated results for the six and\nthree months ended June 30, 2026.\n\nInnocan's consumer wellness subsidiary. B.I. Sky Global Ltd. (\"BI Sky\"),\nsuccessfully maintained a gross margin of 90.9% during the period, reflecting\nthe strength of its product portfolio, direct-to-consumer business model and\ndisciplined approach to operations.\n\nVALITIC™ Maintains Leading Amazon Best Seller Position\n\nVALITIC™, the flagship skincare brand of B.I. Sky, continues to maintain a\nleading positions across key product categories on Amazon, including achieving\nthe leading ranking in its category. This performance reflects continued\nconsumer demand and the growing strength of the VALITIC™ brand.\n\nVALITIC™ continues to hold Amazon's \"Best Seller\" badge, recognizing its\nposition as the Top best-selling product in its specific category. The badge\nis based on actual sales performance rather than customer ratings and is\nupdated hourly according to sales volume, highlighting the brand's strong and\nsustained consumer demand.\n\nVALITIC™ also holds Amazon's Choice recognition, reflecting Amazon's\nalgorithmic recommendation based on factors including customer ratings, price\ncompetitiveness, availability, delivery performance and return rates.\n\n\"We are proud of the strength of BI Sky's business and the consumer trust\nbuilt around our products,\" said Iris Bincovich, CEO of Innocan Pharma\nCorporation. The Company's results were also impacted by the Trump\nadministration's frequently changing policies regarding customs duties and\ntariffs, which created significant uncertainty that led to a decline in sales\nin the period. However, the Company continues to maintain a strong balance\nsheet and solid liquidity position, with approximately $ US 6.4 million in\ncash and cash equivalents and $US10.37 million in total assets as of June 30,\n2026, providing a solid consolidated financial foundation to support its\nongoing operations and growth initiatives.\n\nRoni Kamhi, CEO of B.I. Sky  and COO of Innocan Pharma said \"Building on Our\nTop Amazon Ranking to Expand Sales Across Multiple Channels B.I. Sky is\nadvancing initiatives to diversify and expand its sales channels, building on\nits leading position on Amazon while broadening its market reach across\nmultiple platforms.\n\nAmazon will continue to represent an important sales channel. At the same\ntime, the Company is pursuing additional growth opportunities, including\nexpanding its relationships with major U.S. retail and distribution networks\nand increasing its presence across major online retail platforms. In parallel,\nB.I. Sky has begun selling through its own direct-to-consumer (DTC) website,\nwhich is already operational and provides an additional platform to build\ndirect relationships with consumers, strengthen brand engagement, and expand\nthe reach of the Valitic® brand.\nI believe that its established brands, product portfolio and existing customer\nbase provide a strong foundation for further growth. By leveraging these\nstrengths across a broader range of sales channels, the Company aims to\nincrease market reach, create additional revenue opportunities and strengthen\nits commercial performance. I expect these initiatives to support revenue\ngrowth and expand the reach and visibility of its brands over the coming year.\n\n\"With a greater focus on sales execution, broader distribution and continued\ninvestment in our core strengths, we believe B.I. Sky is well positioned to\nstrengthen its commercial performance and create long-term value for our\nshareholders,\" concluded Mr. Kamhi.\n\nFISCAL 2026 THREE MONTHS SELECT FINANCIAL RESULTS (unaudited) Consolidated\n\n (US$ in millions)        Three Months Ended      Percentage   \n                          June 30,                Change       \n                          2026        2025        \n Revenues                 5.25        7.01        (25.06 %)    \n Gross Profit             4.769       6.195       (23.0 %)     \n Gross Margin             90.8 %      88.4 %                   \n Operating Profit (Loss)  (0.508)     0.396       (228.3 %)    \n* Revenues totaled US$5.25 million for the three months ended June 30, 2026,\nOn a year-over-year basis, revenues decreased 25.06% compared to the same\nperiod in the prior year.\n* Gross Profit totaled US$4.769 million representing a decrease of 23.0% on a\nreported basis for the three months ended June 30, 2026.\n* Gross Margin remained high at 90.8% despite the decline in revenues in three\nmonths ended June 30, 2026.\n* Operating loss totaled US$0.508 million, representing an increase of 228.3%\non a reported basis for the three months ended June 30, 2026.\nThe Company's full set of unaudited condensed interim consolidated financial\nstatements for the three and six months ended June 30, 2026, and accompanying\nmanagement's discussion and analysis can be accessed by visiting the Company's\nwebsite at www.innocanpharma.com and its SEDAR+ profile\nat www.sedarplus.ca.\n\nAbout Innocan:\n\nInnocan is an innovator in the pharmaceuticals and wellness sectors. In the\nwellness sector, Innocan develops and markets a wide portfolio of\nhigh-performance self-care and beauty products to promote a healthier\nlifestyle. Under this segment Innocan carries on business through its 60%\nowned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted\nonline sales.\n\nwww.innocanpharma.com \n\nContact Information:\n\nFor Innocan Pharma Corporation:\nIris Bincovich, CEO\n+1 5162104025\n+972-54-3012842\n+442037699377\ninfo@innocanpharma.com\n\nNEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER\nHAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS\nRELEASE.\n\nCaution Regarding Forward-Looking Information\n\nCertain information set forth in this news release, including, without\nlimitation,  consumer growth of the Valitic brand, is forward-looking\ninformation within the meaning of applicable securities laws. By its nature,\nforward-looking information is subject to numerous risks and uncertainties,\nsome of which are beyond Innocan's control. The forward-looking information\ncontained in this news release is based on certain key expectations and\nassumptions made by Innocan, including expectations and assumptions concerning\nthe anticipated benefits of the products, satisfaction of regulatory\nrequirements in various jurisdictions and satisfactory completion of\nproduction and distribution arrangements.\n\nForward-looking information is subject to various risks and uncertainties that\ncould cause actual results and experience to differ materially from the\nanticipated results or expectations expressed in this news release. The key\nrisks and uncertainties include but are not limited to: global and local\n(national) economic, political, market and business conditions; governmental\nand regulatory requirements and actions by governmental authorities; and\npotential disruption of relationships with suppliers, manufacturers,\ncustomers, business partners and competitors. There are also risks that are\ninherent in the nature of product distribution, including import/export\nmatters and the failure to obtain any required regulatory and other approvals\n(or to do so in a timely manner). The anticipated timeline for entry to\nmarkets may change for a number of reasons, including the inability to secure\nnecessary regulatory requirements, or the need for additional time to conclude\nand/or satisfy the manufacturing and distribution arrangements. As a result of\nthe foregoing, readers should not place undue reliance on the forward-looking\ninformation contained in this news release. A comprehensive discussion of\nother risks that impact Innocan can be found in Innocan's public reports and\nfilings which are available under Innocan's profile at www.sedarplus.ca.\n\nReaders are cautioned that undue reliance should not be placed on\nforward-looking information as actual results may vary materially from the\nforward-looking information. Innocan does not undertake to update, correct or\nrevise any forward-looking information as a result of any new information,\nfuture events or otherwise, except as may be required by applicable law.\n\nLogo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg\n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-second-quarter-fiscal-year-2026-results-with-revenue-of-us5-25m-cad-7-3m-302865166.html\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-31T20:01:00.556926235Z","server_sent_at_ms":1788206460556},"received_at":"2026-08-31T20:01:00.615Z","source_url":null},"analysis":{"id":"120398","press_release_id":"131486","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["revenue down 25.06% year-over-year","swung to operating loss of $0.51M","headwinds from tariffs/customs duties"],"eventType":"earnings","narrative":"Innocan Pharma reported Q2 revenue of US$5.25 million, a 25% year-over-year decline, citing tariff headwinds that pressured sales and contributed to an operating loss.\n\nDespite the top-line drop, gross margin remained robust at 90.9%, supported by subsidiary B.I. Sky's VALITIC brand retaining its Amazon Best Seller status.\n\nThe company maintained a strong balance sheet with US$6.4 million in cash and plans to diversify sales channels beyond Amazon to drive future growth.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong margins masked by sales hit; pivot to new channels underway."},"keyFigures":{"revenue":5250000,"customDimensions":{"gross_margin":"90.9%","total_assets":10370000,"cash_and_equivalents":6400000}},"quotedText":"We are proud of the strength of BI Sky's business and the consumer trust built around our products","namedEntities":{"people":[{"name":"Iris Bincovich","role":"CEO"},{"name":"Roni Kamhi","role":"CEO of B.I. Sky and COO of Innocan"}],"products":["VALITIC"],"companies":[{"name":"Innocan Pharma Corporation","ticker":"IP40"},{"name":"B.I. Sky Global Ltd.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"US$5.25M","context":"Second Quarter Revenue"},{"amount":"US$6.4 million","context":"cash and cash equivalents"},{"amount":"$US10.37 million","context":"total assets"}]},"materialImpact":{"score":3,"reasoning":"Revenue declined 25% year-over-year and the company swung to an operating loss, driven by tariff headwinds. However, gross margins remain high at 90.9% and the balance sheet is solid."},"tickerRelevance":{"others":[{"ticker":"INNO","relevance":"mentioned"},{"ticker":"INNPF","relevance":"mentioned"}],"primary":"IP40"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"earnings_miss","sectorWeight":"low"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Innocan Pharma reported Q2 revenue of US$5.25 million, a 25% year-over-year decline, citing tariff headwinds that pressured sales and contributed to an operating loss.\n\nDespite the top-line drop, gross margin remained robust at 90.9%, supported by subsidiary B.I. Sky's VALITIC brand retaining its Amazon Best Seller status.\n\nThe company maintained a strong balance sheet with US$6.4 million in cash and plans to diversify sales channels beyond Amazon to drive future growth.","key_figures":{"revenue":5250000,"customDimensions":{"gross_margin":"90.9%","total_assets":10370000,"cash_and_equivalents":6400000}},"named_entities":{"people":[{"name":"Iris Bincovich","role":"CEO"},{"name":"Roni Kamhi","role":"CEO of B.I. Sky and COO of Innocan"}],"products":["VALITIC"],"companies":[{"name":"Innocan Pharma Corporation","ticker":"IP40"},{"name":"B.I. Sky Global Ltd.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"US$5.25M","context":"Second Quarter Revenue"},{"amount":"US$6.4 million","context":"cash and cash equivalents"},{"amount":"$US10.37 million","context":"total assets"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T20:10:54.295Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"earnings_miss","sectorWeight":"low"}},"durationMs":152795,"modelName":"glm-4.7"}}